Pre-surgical immunotherapy plus chemotherapy improves patient outcomes in operable lung cancer:Study
#clinicaltrials #chemotherapy #cancerpatients #lungcancer #drugcombinations #cancerresearch #researchorganizations #cancerimmunotherapy #cellpathology #cellresponses #gutmicrobiota #lungtumors #primarytumors
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
New findings from the NEOSTAR trial, published in Nature Medicine, provide further support for neoadjuvant immunotherapy-based treatment as an approach to reduce viable tumor at surgery and to improve outcomes in NSCLC. The combination also was associated with an increase in immune cell infiltration and a favorable gut microbiome composition.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
-
Category
No comments found